****

**Original Article**

**Clinical Performance of the *Aspergillus* Western Blot IgG Kit for Serodiagnosis of Chronic Pulmonary Aspergillosis in Post-Tuberculosis Patients**

***Anna Rozaliyani1,2,3, Sresta Azahra******4, Findra Setianingrum1,3, Heri Wibowo1,3***

*1 Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia*

*2 The Indonesian Society of Respirology, Jakarta, Indonesia*

*3 The Indonesia Pulmonary Mycoses Centre Faculty of Medicine Universitas Indonesia –* National Respiratory Referral Hospital Persahabatan*, Jakarta, Indonesia*

*4 Magister Program of Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia*

|  |  |
| --- | --- |
| **Abstract** **Background:** Chronic pulmonary aspergillosis (CPA) due to *Aspergillus* spp.,causing slowly progressive destruction to lung parenchyma, is a major complication of pulmonary tuberculosis (TB). The clinical and radiological features of CPA are not typical and might resemble TB. Therefore, detecting *Aspergillus*-specific IgG is critical for diagnosing CPA.**Methods:** This cross-sectional study was conducted to evaluate the performance of *Aspergillus* Western Blot (Asp-WB) IgG kit (LDBio Diagnostics, Lyon, France) for CPA diagnosis in 63 post-TB patients. The analysis was carried out by comparing Asp-WB with *Aspergillus* ELISA IgG (Asp-ELISA) and fungal culture as standard method.**Results:** Of the 63 patients studied, twenty six (41%) met the probable CPA criteria. The Asp-WB results were positive in 13 probable CPA patients and 3 non-CPA patients, with the significant difference of 50% vs. 8% (p< 0.001). The sensitivity and specificity of Asp-WB were 50% and 93%. False negative results of Asp-WB were detected from non-fumigatus CPA that grew *Aspergillus niger.* CPA patients with mild symptoms (less than 3 months) indicated early progression of CPA might showed positive Asp-WB test result in low sensitivity of Asp-WB test.**Conclusion:** The Asp-WB has potential to use as confirmatory test to assist diagnosis of CPA in post-TB patients. **Keywords:** Western blot, chronic pulmonary aspergillosis, tuberculosis | **Corresponding Author:***Anna Rozaliyani* | Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia | annaroza1110@gmail.com**Submitted:** ……………..**Accepted:** ………………**Published:** ……………….**J Respirol Indones. 2021****Vol. 1 No. 2: 150-160**<https://doi.org/10.36497/respirsci.v1i2.20>  |

**INTRODUCTION**

Pulmonary tuberculosis (PTB) is still a serious problem in Indonesia. About 8.5% of global TB cases are located in Indonesia, a country with the second-highest TB burden in the world.1 Pulmonary TB can cause damage to lung tissue, making it easier for the adhesion and invasion of *Aspergillus,* which can lead to chronic pulmonary aspergillosis (CPA) in certain cases.2–6 It affects approximately 1.2 million individuals with CPA as a sequel of PTB.7

The prevalence of CPA is estimated at 378,700 cases in Indonesia.8 The incidence rate of CPA in the end of TB therapy in previous study was 8%.9 The CPA diagnosis is still challenging because of the atypical clinical manifestations, radiology findings and the low sensitivity of the fungal culture. Detection of antibodies against *Aspergillus* might facilitate the accurate diagnosis of CPA. Prior study categorised the diagnosis of CPA into probable and proven CPA. Probable CPA may represent early-stage CPA or the limited radiology information due to lack of thorax CT scan, so the lung cavity is undetectable.

The enzyme-linked immunosorbent assays (ELISAs) and immunoprecipitin detection (IPD) are widely used to detect specific anti-*Aspergillus* antibodies.10–13 However, those tests have drawbacks, including time-consuming, lack of standardisation, and extended turnaround times. The *Aspergillus* Western Blot IgG kit (*Asp*-WB) has been commercialised (LDBio Diagnostics, Lyon, France) using *A. fumigatus* glycoprotein antigen with a molecular weight of 16 kD, 18-20 kD, 22 kD, and 30 kD.14–16 Study on Asp-WB for diagnosing of CPA are still limited in Indonesia. This study aimed to evaluate the accuracy of Asp-WB compare to consensus results of fungal cultures and Asp-ELISA to support CPA diagnosis in post-TB patients.

**METHODS**

This cross-sectional study is part of the prior study on CPA diagnostics in Indonesia. Sera were collected from 63 previous TB patient who had persistent symptoms after the completion of TB therapy. Probable CPA was diagnosed based on the three parameters:1) *Aspergillus* culture positive and/or positive *Aspergillus* antibody test including immunochromatography (ICT) or Western Blot (WB) methods, AND 2) at least one of these symptoms including cough, dyspnea, chest pain, haemoptysis, and/or fatigue within >3 months, OR 3) radiological features indicative of CPA (at least one of cavitation and/or fungal ball)***.*** The study was performed at the Parasitology Laboratory, FMUI. It was approved by Health Research Ethics Committee of FMUI through the Ethics Review No. 95/UN2.F1/ETIK/2019.

***Aspergillus* Western Blot IgG test:** 1,2 ml of buffer solution was added to each incubation tray with a strip in it. Samples and controlled was added by 10 µl and incubated for 90 minutes. The solution was washed by buffer solution (1:10) three times. Then, 1,2 ml anti IgG conjugate was added and incubated for 60 minutes. The solution was rewashed, and 1,2 ml of substrate was dispensed depending on the strip coloration and incubated for 60 minutes. The strips were left to dry for at least 15 minutes at room temperature. The results were contrasted to the positive control and determined as positive or negative according to the manufacturer. *Aspergillu*s-specific sensitization was proved by four protein bands at 16, 18 to 20, 22, and 30 kDa. The result was positive when at least two of these bands were documented (Fig. 1A). The Asp-WB global intensity were scored from 1 to 4 by summing the results of each specific band (Fig. 1B). Asp-WB intensity was categorized as very high (>10), high (5 to 10), moderate (2 to 4), and weak (<2). Each test was carried out in duplicate and read by two experts.16



**(C)**

**(B)**

**(A)**

Figure 1. *Asp*-WB results.

(A) C+ positive control; the mass (in kDa) of the specific bands shown by values on next to the arrows. (B) NC, negative control. (C) Quantification of *Asp*-WB band intensity in a positive assay; the intensities of four specific bands were 3, 3, 4, and 3, respectively, yielding a global intensity of 13.

***Aspergillus* ELISA IgG test:** The sera were tested using the IgG-specific *Aspergillus* antibody with ELISA indirect method. As 100 µl diluted sample, standard and controlled solution were taken by pipets, then put in the well and incubated for 60 minutes. The solution was washed three times with washing solution (1:20). Anti-IgG conjugate was added to the solution and incubated for 30 minutes. The solution was rewashed and added a substrate solution. It was incubated for 15 minutes, then added a stopping solution. It was read using ELISA reader with wavelength 450 nm which gain the result such as cut-off positive result ≥120 AU/ml, negative <80 AU/ml, and inconclusive 80-110 AU/ml.

**Statistical Analysis:**Diagnostic potential in this study was assessed based on the sensitivity test and specificity test. Data were presented using frequencies and percentages for binary and categorical variables. Fisher’s exact tests or chi-squared tests were used for categorical variables. Statistical analysis was performed with the use of IBM SPSS 22 statistic software.

**RESULTS**

Sixty-three sera from post-TB patients were included in the study (Table 1). Twenty-six (41%) out of 63 patients met the criteria for probable CPA. The main symptoms in the probable CPA cases were dyspnea (n=10, 38%) and fatigue (n=10, 38%).

Table 1. Demography of post-TB patients

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Symptoms** | **ALL****(n=63)** | **CPA****(n=26)** | **Non-CPA (n=37)** | **p-value** |
| Gender |  |  |  |  |
|  Male | 42 (67%) | 19 (73%) | 23 (62%) |  |
|  Female | 21 (33%) | 7 (27%) | 14 (38%) | 0.366 |
| Mean age (range in years) |  |  |  |  |
|  > 60 years | 16 (25%) | 7 (27%) | 9 (24%) |  |
|  < 60 years | 47 (75%) | 19 (73%) | 28 (76%) | 0.816 |
| **Sign & symptoms (>3 months)** |  |  |  |  |
|  Cough | 19 (30%) | 9 (35%) | 10 (27%) | 0.518 |
|  Haemoptysis | 11 (18%) | 4 (15%) | 7 (19%) | 1 |
|  Dyspnea | 22 (35%) | 10 (38%) | 12 (55%) | 0.621 |
|  Chest pain | 10 (16%) | 4 (15%) | 6 (16%) | 1 |
|  Fatigue | 26 (41%) | 10 (38%) | 16 (43%) | 0.704 |

Among 63 patients, the strong positive and weak positive rate of Asp-WB tests were 13% (n=8) equally, which together result in 25% (n=16) positives. In the probable CPA group, 13 of 26 sera tested had positive results by Asp-WB with 50% sensitivity. In the non-CPA group, 34 of the 37 sera showed negative results by WB with 92% specificity. The Asp-WB results were positive in 13 probable CPA patients and three non-CPA patients, with the significant difference of 50% vs. 8% (p< 0.001). Fifteen percent (n=4) of probable CPA group showed three bands in Asp-WB test, which is significantly higher compare with no patients (0%) in non-CPA group (p=0.025).

The 16 kDa WB band was the most prevalent (30%) bands among 63 patients (Table 2). The proportion of all four WB bands (50% vs. 16% for 16 kDa, 46% vs. 14% for 18–20 kDa, 35% vs. 3% for 22 kDa and 27% vs. 5% for 30 kDa) was significantly higher in the CPA group than in non-CPA group (p<0.05 in all the bands)

Table 2. The result of Asp-WB based on antigen characterization

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Antigen characterization (molecular weight)** | **Total (n=63)** | **CPA (n=26)** | **Non-CPA (n=37)** | **p-value** |
| 16 kD | 19 (30%) | 13 (50%) | 6 (16%) | 0.004 |
| 18-20 kD | 17 (27%) | 12 (46%) | 5 (14%) | 0.004 |
| 22 kD | 10 (16%) | 9 (35%) | 1 (3%) | 0.001 |
| 30 kD | 9 (14%) | 7 (27%) | 2 (5%) | 0.026 |

The Asp-ELISA and Asp-WB tests require sensitivity and specificity values for becoming proper diagnostic tools. The tests should have good accuracy, precision, and reliability. The sensitivity and specificity of Asp-ELISA and Asp-WB compared with the combination methods (fungal culture results and positive Ab detection, either with one or both methods) as a standard diagnostic method.

**DISCUSSION**

The evaluation of Asp-WB test performance to diagnose CPA in post-TB patients have been carried out in this study. The assay showed 50% sensitivity and 92% specificity for diagnosis of probable CPA. The relatively lower sensitivity compare with previously described study might be related to different population and the criteria used to diagnose CPA. Previous study using 88 post-TB patients with GeneXpert negative showed 80% sensitivity and 70% specificity of Asp-WB test to diagnose proven CPA.15 Asp-WB test showed high specificity with only three false positive. These three patients had weak positive band of Asp-WB test, but the radiology and the symptoms were not fulfilled criteria of CPA.

However, the growths of *Aspergillus* could be documented in the sputum of those three patients; one patient had *A. flavus*, one patient had *A. niger*, and one patient had *A. flavus* and *A. niger*. All these patients came to the clinic with pulmonary symptoms such as cough, dyspnea, and chest pain, but less than three months. The presence of minimal symptoms might indicate the early stage of CPA.

Eight out of thirteen patients with false negative Asp-WB test had *A. niger* in their culture. *Aspergillus niger* were solely found in five patients, while *A. niger* grew together with *A. flavus* and *A. fumigatus* in three patients. Previous study revealed 38% of *Aspergillus* section *Nigri* as the etiology of CPA in Indonesia.17 All the Asp-antibody detection kit that available now are based on the *A. fumigatus* antigen.14 Therefore, these eight patients appeared as false negative results was likely because the presence of antibody that specific to non-fumigatus infections (for example *A. niger*). These types of antibodies were not detected using the Asp-WB test that was specific for *A. fumigatus* infection.

The Asp-WB test is part of diagnostic scheme, as the point-of-care test (POCT) of CPA, particularly in limited-resource settings. The Asp-WB test was then less popular for routine use as POCT due to several issues, including the limitation of ELISA facilities and less economical costs.

Further development of CPA diagnostic tests is by using the lateral flow assay (LFA) method. The test becomes more feasible for POCT of CPA because it is very simple, fast and inexpensive. The LFA-based test is more suitable for routine CPA screening. Meanwhile, the high specificity of Asp-WB test make it more feasible for confirmatory test of CPA. The serial Asp-WB test also has more potential for assessing the disease course of CPA, as well as evaluating treatment, in accordance with the clinical judgment.

**STUDY LIMITATION**

The limitation of this study including the lack of serial Asp-WB tests and availability of thorax CT-scan. We used chest x-ray to detect suggestive CPA findings which might not reliably detect the cavities as good as CT-scan.

**CONCLUSION**

In conclusion, the clinical and radiological appearances of CPA might resemble TB. Therefore, the antibody test such as Asp-WB test is critical to assist the diagnosis of CPA. The specificity of Asp-WB test is high, so this test can be used as confirmatory test to diagnose CPA.

**ACKNOWELEDGMENTS**

The authors gratefully acknowledge the staff of the Department of Pulmonology and Respiratory Medicine FMUI for the collaboration in patients’ recruitment, Chris Kosmidis and David Denning for international research collaboration, and the staff of the Department of Parasitology FMUI for laboratory work.

**CONFLICT OF INTERESTS**

There is no conflict of interests.

**FUNDING**

This study received financial support from The Indonesia Pulmonary Mycoses Centre (IPMC) FMUI- Persahabatan National Respiratory Referral Hospital for the purpose of an epidemiological survey.

**REFFERENCES**

1. WHO. Global tuberculosis report 2021. Geneva: World Health Organization; 2021.

2. Page ID, Byanyima R, Hosmane S, Onyachi N, Opira C, Richardson M, et al. Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation. Eur Respir J. 2019;53(3).

3. Chakaya J, Kirenga B, Getahun H. Long term complications after completion of pulmonary tuberculosis treatment: a quest for a public health approach. J Clin Tuberc Other Mycobact Dis.2016;3:10-2.

4. Rozaliyani A, Rosianawati H, Handayani D, Agustin H, Zaini J, Syam R, et al. Chronic pulmonary aspergillosis in post tuberculosis patients in indonesia and the role of ldbio aspergillus ict as part of the diagnosis scheme. J Fungi (Basel). 2020;6(4):318.

5. Nguyen NTB, Le Ngoc H, Nguyen NV, Van Dinh L, Van Nguyen H, Nguyen HT, et al. Chronic pulmonary aspergillosis situation among post tuberculosis patients in Vietnam: An observational study. J Fungi (Basel).2021;7(7):532.

6. Lakhtakia L, Spalgais S, Kumar R. Spectrum of pulmonary aspergillus diseases in post TB lung diseases. Indian J Tuberc. 2022;69(4):523-9.

7. Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bulletin of the World Health Organization.2011; 89(12):864-72.

8. Wahyuningsih R, Adawiyah R, Sjam R, Prihartono J, Ayu Tri Wulandari E, Rozaliyani A, et al. Serious fungal disease incidence and prevalence in Indonesia. Mycoses. 2021;64(10):1203-12.

9. Setianingrum F, Rozaliyani A, Adawiyah R, Syam R, Tugiran M, Sari CYI, et al. A prospective longitudinal study of chronic pulmonary aspergillosis in pulmonary tuberculosis in Indonesia (APICAL). Thorax. 2022;77(8):821-8.

10. Denning DW, Page ID, Chakaya J, Jabeen K, Jude CM, Cornet M, et al. Case definition of chronic pulmonary aspergillosis in resource-constrained settings. Emerg Infect Dis. 2018;24(8):e1-13.

11. Page ID, Richardson MD, Denning DW. Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA). J Infect. 2016;72(2):240–9.

12. Page ID, Richardson MD, Denning DW. Siemens immulite aspergillus-specific IgG assay for chronic pulmonary aspergillosis diagnosis. Med Mycol. 2019;57(3):300-7.

13. Baxter CG, Denning DW, Jones AM, Todd A, Moore CB, Richardson MD. Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis. Clin Microbiol Infect. 2013;19(4):E197-204.

14. Richardson M, Page I. Role of Serological Tests in the Diagnosis of Mold Infections. Current Fungal Infection Reports. 2018;12:127-36.

15. Rozaliyani A, Setianingrum F, Azahra S, Abdullah A, Fatril AE, Rosianawati H, et al. Performance of ldbio aspergillus wb and ict antibody detection in chronic pulmonary aspergillosis. J Fungi (Basel).2021;7(4):311.

16. Oliva A, Flori P, Hennequin C, Dubus JC, Reynaud-Gaubert M, Charpin D, et al. Evaluation of the Aspergillus Western blot IgG kit for diagnosis of chronic aspergillosis. J Clin Microbiol. 2015;53(1):248-54.

17. Rozaliyani A, Abdullah A, Setianingrum F, Sjamsuridzal W, Wahyuningsih R, Bowolaksono A, et al. Unravelling the Molecular Identification and Antifungal Susceptibility Profiles of Aspergillus spp. Isolated from Chronic Pulmonary Aspergillosis Patients in Jakarta, Indonesia: The Emergence of Cryptic Species. J Fungi (Basel). 2022;8(4):411.